This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing primary Membranous Nephropathy and the potential of Eliem Therapeutics' TNT119, an anti-CD19 mAB
Ticker(s): ELYMWho's the expert?
Institution: UPENN
- Associate Professor of Clinical Medicine and the Clinical Director, Glomerular Diseases Program at University of Pennsylvania.
- Currently manages 100 patients with IgAN, 1000 patients with CKD, and 15 patients with C3 glomerulopathy.
- Research focuses on Glomerular diseases, Onconephrology, and kidney biopsy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
